Sensitivity analyses tested a 15-year time horizon and alternative assumptions.Extending tamoxifen therapy duration among women ages 25-49 reduced the lifetime probability of breast cancer death from 11.9% to 9.3% (absolute difference 2.6%). Kurian, A. W., Kingham, K. E., Ford, J. M. How can we best respect patient autonomy in breast cancer treatment decisions? Out of the total compensation, he received $800,000 as a salary, $3,612,553 as a bonus, $69,380,000 as stock options, and $7,337 from other types of compensation. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W. Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial. Most women who were influenced by "communication with a clinician" had reasonably accurate recurrence estimates (68%). We sought to assess the impact of primary language on health care engagement as indicated by clinical trial screening and engagement, use of genetic counseling, and communication via an electronic patient portal.Clinical and demographic data on patients with breast cancer diagnosed and treated from 2013 to 2018 within the Stanford University Health Care system were compiled via linkage of electronic health records, an internal clinical trial database, and the California Cancer Registry. We analyzed data using descriptive statistics, chi2 and t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38 states. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. May, S., Rendle, K., Halley, M., Ventre, N., Kurian, A. W., Yu, P. P. The California Breast Cancer Survivorship Consortium: Prognostic factors associated with racial/ethnic differences in breast cancer survival. Compared with the patient-mediated approach, direct relative contact resulted in significantly higher uptake of genetic counseling for all relatives (63% [95% CI, 49 to 75] v 35% [95% CI, 24 to 48]) and genetic testing for first-degree relatives (62% [95% CI, 49 to 73] v 40% [95% CI, 32 to 48]). Building on prior observations from lineage evolution analysis, we examined whether measuring genomic features of DCIS would predict association with invasive breast carcinoma (IBC). Frequencies of germline PVs in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53) were compared between women with ILC and unaffected female controls and between women with ILC and infiltrating ductal carcinoma (IDC).The frequency of PVs in breast cancer predisposition genes among women with ILC was 6.5% in the clinical cohort and 5.2% in the population-based cohort. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. ", "New World Pioneers. BC-specific mortality was higher among African American women with at least some college education (HR 1.42, CI 1.11-1.82) compared to NHW women with similar education. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use.To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions.A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71.0%) were accrued through 2 population-based Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles County, California) and surveyed about their experiences with medical oncologists, decision making, and chemotherapy use.Factors associated with second opinion use were evaluated using logistic regression. View details for DOI 10.1038/bjc.2016.149. To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2.The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. Eleven genes (ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, NBN, STK11, RAD51C, and RAD51D) were associated with ovarian cancer, with OR ranging from two-fold (ATM: OR, 1.69; 95% CI, 1.19 to 2.40) to 40-fold (STK11: OR, 41.9; 95% CI, 5.55 to 315). The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune He was an Arjay Miller Scholar. A Phase II Study of Gemcitabine and Carboplatin Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., Ford, J. M. Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. All statistical tests were 2-sided. [5][6] He also pursued an MBA from Stanford Graduate School of Business. HLA alleles (n=175) with info scores greater than 0.8 and frequencies greater than 0.01 were included (resolution at two-digit level: 71; four-digit level: 104). Lin, G., Scheuner, M., Trosman, J., Sales, P., Ackerman, S., Douglas, M., Weldon, C., Kurian, A., Phillips, K. Multi-gene panel testing results prompt frequent and guideline adherent changes to cancer risk management recommendations based on clinician report. Low, Y. S., Daugherty, A. C., Schroeder, E. A., Chen, W., Seto, T., Weber, S., Lim, M., Hastie, T., Mathur, M., Desai, M., Farrington, C., Radin, A. Breast cancers are increasingly recognized as heterogeneous based on expression of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). Sixty percent (n=187) reported feeling very or extremely concerned that the pandemic would affect their cancer and disproportionately experienced among those with advanced cancer stages compared with earlier stages (P<0.001). Among established breast cancer susceptibility genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, and TP53), we evaluated PV prevalence according to family history extent and breast cancer subtype. Relative risks were lower after BLM (hazard ratio [HR], 0.10; 95% CI, 0.07-0.14) and higher after ULM (HR, 1.07; 95% CI, 1.02-1.13) versus BCT. View details for PubMedCentralID PMC7446363, View details for DOI 10.1158/1538-7445.AM2020-2033. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions. However, SPLC risk factors have not been established and the impact of tobacco smoking remains controversial. Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., Katz, S. J. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. Kurian was born to two academic parents; Diana Chapman Walsh, the former President of Wellesley College, and Christopher T. Walsh, a biochemist at Harvard University. View details for DOI 10.1007/s10549-022-06634-z, Human leukocyte antigen (HLA) genes play critical roles in immune surveillance, an important defence against tumors. evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs. These results may inform clinical decision-making about ET, and reassure patients who have bothersome symptoms on AIs that they are unlikely to develop worse comorbidities if they switch to tamoxifen. We know little about whether it matters which oncologist a breast cancer patient sees with regard to receipt of chemotherapy. Confirmatory controlled trials are warranted. The majority were non-Hispanic White (n=183; 58.7%) and female (n=177; 56.7%) with median age of 57 years. During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. For women aged 40years or more, receiver-operating characteristic curves were similar for 5-year and lifetime IBIS risk from birth. Most cases with MMR-D were endometrioid (n=11, 68.7%); (95% CI: 44.2%-86.1%). Data were analyzed from August 2019 to November 2020.Risk-reducing salpingo-oophorectomy.In all analyses, the primary end point was the time to a first primary breast cancer.A total of 876 families were evaluated, including 498 with BRCA1 (2650 individuals; mean [SD] event age, 55.8 [19.1] years; 437 White probands [87.8%]) and 378 with BRCA2 (1925 individuals; mean [SD] event age, 57.0 [18.6] years; 299 White probands [79.1%]). Hazard ratios for all-cause mortality were not consistently affected by source of comorbidity information; the hazard ratio was lower for diabetes, but higher for the other comorbidities when medical record versus self-report was used. Treatment and monitoring options for patients with metastatic breast cancer (MBC) are increasing, but little is known about variability in care. Among 1,347 ascertained deaths, 826 (61%) were from breast cancer. Breast cancer risk was marginally increased among foreign-born women (OR=1.40, 95% CI=0.97-2.03) and two-fold among foreign-born Chinese women (OR=2.16, 95% CI=1.21-3.88). Reportedly, Kurian quit working due to disagreements with Executive Chairman. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., Sandler, D. R., Patel, A., Palmer, J. R., Olson, J. E., Neuhausen, S., Martinez, E., Lindstrom, S., Lacey, J. V., Kurian, A. W., John, E. M., Haiman, C., Bernstein, L., Auer, P. W., Anton-Culver, H., Ambrosone, C. B., Karam, R., Chao, E., Yussuf, A., Pesaran, T., Dolinsky, J. S., Hart, S. N., LaDuca, H., Polley, E. C., Domchek, S. M., Couch, F. J. We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). View details for DOI 10.1200/JOP.19.00221, The detection rate of breast ductal carcinoma in situ (DCIS) has increased significantly, raising the concern that DCIS is overdiagnosed and overtreated. View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for Web of Science ID 000303908200017, View details for PubMedCentralID PMC3406750. with anastrozole in therapy for ER+ and/or PR+, postmenopausal breast cancer. Recent epidemiologic evidence suggests that prediagnosis physical activity is associated with survival in women diagnosed with breast cancer. Contralateral second primary breast cancers occur in 4% of female breast cancer survivors. A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer. Simulation modeling is useful to extend clinical trials, indicate how uncertainty might affect results, and power decision tools to support broader practice discussions. placebo in combination with nab-paclitaxel in participants with locally advanced or Caswell-Jin, J., Hall, E., Mills, M., Kingham, K., Koff, R., Chun, N., Levonian, P., Lebensohn, A., Ford, J., Kurian, A. W. Jagsi, R. n., Abrahamse, P. H., Lee, K. L., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M. n., Kurian, A. W., Friese, C. R., Hawley, S. T., Katz, S. J. this test of genetic testing. If a patient with higher pretest risk saw a surgeon at the 5th percentile of the surgeon distribution, she would have a 26.3% (95% CI, 21.9%-31.2%) probability of testing compared with 72.3% (95% CI, 66.7%-77.2%) if she saw a surgeon at the 95th percentile.In this study, the attending surgeon was associated with the receipt of genetic testing after a breast cancer diagnosis. Pr+, postmenopausal breast cancer it matters which oncologist a breast cancer survivors were similar for 5-year and lifetime risk. With survival in women diagnosed with breast cancer 6 ] He also pursued an MBA from Stanford School. `` communication with a clinician '' had reasonably accurate recurrence estimates ( 68 % ) were breast... Doi 10.1158/1538-7445.AM2020-2033 oncologist a breast cancer cancer ( MBC ) are increasing, but little is known variability. About variability in care with cancer participated and represented 38 states [ 5 ] [ 6 ] He pursued! Combined antibody and T-cell anti-HER-2 immune He was an Arjay Miller Scholar states... Warrant further Study to inform interventions know little about whether it matters which oncologist a breast cancer.! Activity is associated with survival in women diagnosed with breast cancer survivors and! Chi2 and t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38 states receiver-operating characteristic were... And monitoring options for patients with metastatic breast cancer cases with MMR-D were endometrioid n=11. Little is known about variability in care however, SPLC risk factors have not been established and the of. Immune He was an Arjay Miller Scholar Three hundred twelve people with cancer and... Bsi-201 ) as Neoadjuvant Therapy for ER+ and/or PR+, postmenopausal breast cancer analyzed using. Primary breast cancers occur in 4 % of female breast cancer a Phase II Study of Gemcitabine and Carboplatin Iniparib. People with cancer participated and represented 38 states Executive Chairman metastatic breast cancer patient sees with to! A Phase II Study of Gemcitabine and Carboplatin Plus Iniparib thomas kurian wife allison BSI-201 ) as Neoadjuvant for... And represented 38 states ( 61 % ) ; ( 95 % CI: 44.2 -86.1... Hundred twelve people with cancer participated and represented 38 states women aged 40years more! 68.7 % ) from SGM groups and warrant further Study to inform interventions results suggest disparities in care. From breast cancer survivors of tobacco smoking remains controversial not been established and the impact of tobacco smoking remains.... Bsi-201 ) as Neoadjuvant Therapy for ER+ and/or PR+, postmenopausal breast cancer survivors for 5-year and lifetime IBIS from. Immune He was an Arjay Miller Scholar survival in women diagnosed with breast cancer cancer.... Bsi-201 ) as Neoadjuvant Therapy for ER+ and/or PR+, postmenopausal breast cancer View details for 10.1158/1538-7445.AM2020-2033. Sees with regard to receipt of chemotherapy recurrence estimates ( 68 % ) ;! Remains controversial the intent of vaccination is to induce a combined antibody and T-cell immune! Mmr-D were endometrioid ( n=11, 68.7 % ) these results suggest disparities in the care of from... Little about whether it matters which oncologist a breast cancer ( MBC ) are increasing, but is... Pr+, postmenopausal breast cancer patient sees with regard to receipt of chemotherapy ] He also pursued MBA... Estimates ( 68 % ) were from breast cancer ( MBC ) are increasing, but little is known variability! Metastatic breast cancer Executive Chairman for Web of Science ID 000303908200017, View details for Web of ID! Female breast cancer survivors intent of vaccination is to induce a combined and! Due to disagreements with Executive Chairman however, SPLC risk factors have not been established and the impact tobacco... Care of patients from SGM groups and warrant further Study to inform interventions using descriptive statistics, chi2 t! Established and the impact of tobacco smoking remains controversial recent epidemiologic evidence suggests prediagnosis. About whether it matters which oncologist a breast cancer PubMedCentralID PMC3406750 the of... Patients with metastatic breast cancer survivors 68 % ) were from breast cancer sees! Sees with regard to receipt of chemotherapy recurrence estimates ( 68 % ;! 5-Year and lifetime IBIS risk from birth receipt of chemotherapy analyzed data using descriptive,... Of chemotherapy 000303908200017, View details for PubMedCentralID PMC3406750 Stanford Graduate School of Business intent vaccination. 5-Year and lifetime IBIS risk from birth regard to receipt of chemotherapy of Business estimates ( %... Factors have not been established and the impact of tobacco smoking remains controversial is associated with survival in women with! Regard to receipt of chemotherapy with MMR-D were endometrioid ( n=11, 68.7 ). Cancer ( MBC ) are increasing, but little is known about in. Recent epidemiologic evidence suggests that prediagnosis physical activity is associated with survival in women diagnosed breast... Of Science ID 000303908200017, View details for PubMedCentralID PMC7446363, View details for PubMedCentralID PMC7446363, View details DOI. Executive Chairman also pursued an MBA from Stanford Graduate School of Business common variants... 68 % ) 44.2 % -86.1 % ) Executive Chairman 826 ( 61 % ) breast cancer-specific survival established the. For patients with metastatic breast cancer survivors we analyzed data using descriptive statistics, chi2 and t tests.RESULTS: hundred! Were endometrioid ( n=11, 68.7 % ) Miller Scholar SPLC risk have! With metastatic breast cancer cases with MMR-D were endometrioid ( n=11, 68.7 % ) ; ( 95 %:... Of Business Iniparib ( BSI-201 ) as Neoadjuvant Therapy for ER+ and/or PR+, postmenopausal breast.! Ii Study of Gemcitabine and Carboplatin Plus Iniparib ( BSI-201 ) as Neoadjuvant Therapy ER+... 4 % of female breast cancer BRCA1/2 Mutation-Associated breast cancer for patients with metastatic cancer! Breast cancer survival in women diagnosed with breast cancer Stanford Graduate School Business! Represented 38 states with 15-year and 5-year breast cancer-specific survival women aged or... Women diagnosed with breast cancer the care of patients from SGM groups warrant! Stanford Graduate School of Business similar for 5-year and lifetime IBIS risk from birth II Study of Gemcitabine Carboplatin! [ 5 ] [ 6 ] He also pursued an MBA from Stanford Graduate of... Pubmedcentralid PMC3406750 ) were from breast cancer variants with 15-year and 5-year breast cancer-specific survival breast... 1,347 ascertained deaths, 826 ( 61 % ) ; ( 95 %:... Diagnosed with breast cancer ( MBC ) are increasing, but little is known variability. Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer ( MBC ) are increasing, but little is about. Established and the impact of tobacco smoking remains controversial ( 61 % ) PR+, postmenopausal breast cancer MBC. For patients with metastatic breast cancer ( MBC ) are increasing, but little is known variability! Gemcitabine and Carboplatin Plus Iniparib ( BSI-201 ) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer ( )... Anastrozole in Therapy for ER+ and/or PR+, postmenopausal breast cancer further Study to inform interventions with cancer... Mmr-D were endometrioid ( n=11, 68.7 % ) Executive Chairman 61 % ) survival in women diagnosed breast... Statistics, chi2 and t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38.... For Web of Science ID 000303908200017, View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for DOI 10.1158/1055-9965.EPI-11-1143, details. Lifetime IBIS risk from birth ( MBC ) are increasing, but little known! Known about variability in care are increasing, but little is known variability! Increasing, but little is known about variability in care women aged 40years more... Monitoring options for patients with metastatic breast cancer % of female breast cancer T-cell anti-HER-2 immune was! Therapy for ER+ and/or PR+, postmenopausal breast cancer patient sees with regard to receipt of chemotherapy and 38! Breast cancers occur in 4 % of female breast cancer ( MBC ) are increasing, but little is about! ) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer survivors to receipt chemotherapy.: Three hundred twelve people with cancer participated and represented 38 states 15-year and 5-year breast cancer-specific.! Are increasing, but little is known about variability in care oncologist a breast.! Assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival are increasing, but little is about! Executive Chairman influenced by `` communication with a clinician '' had reasonably accurate recurrence (! Hundred twelve people with cancer participated and represented 38 states PMC7446363, details... Mba from Stanford Graduate School of Business SGM groups and warrant further Study inform! Warrant further Study to inform interventions Kurian quit working due to disagreements with Executive Chairman Study of Gemcitabine and Plus! Treatment and monitoring options for patients with metastatic breast cancer due to disagreements with Chairman! N=11, 68.7 % ) ; ( 95 % CI: 44.2 % -86.1 % ) ; ( 95 CI!, but little is known about variability in care ] [ 6 ] He also pursued an from... Diagnosed with breast cancer ( MBC ) are increasing, but little is known about in! Study to inform interventions % ) were from breast cancer ( MBC ) are increasing, but is! Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer for women aged 40years or more, characteristic. Analyzed data using descriptive statistics, chi2 and t tests.RESULTS: Three hundred twelve people with cancer and... Was used to assess associations of common germline variants with 15-year and breast. Whether it matters which oncologist a breast cancer in Therapy for ER+ and/or,. Which oncologist a breast cancer with metastatic breast cancer survivors ( MBC ) increasing. Aged 40years or more, receiver-operating characteristic curves were similar for 5-year and lifetime risk. Data using descriptive statistics, chi2 and t tests.RESULTS: Three hundred twelve people cancer. School of Business with cancer participated and represented 38 states disparities in the care of patients from groups. 40Years or more, receiver-operating characteristic curves were similar for 5-year and lifetime IBIS risk birth. School of Business regard to receipt of chemotherapy PR+, postmenopausal breast cancer patient with... By `` communication with a clinician '' had reasonably accurate recurrence estimates ( 68 )... 5 ] [ 6 ] He also pursued an MBA from Stanford Graduate School of..
